COVID-19 Phase I/II Vaccine Study(English)

• a continuing single-blind phase 1/2 clinical trial in five sites in the UK, which began on April 23, 2020, and enrolled 1077 healthy volunteers aged 18–55 years. Participants were randomly assigned 1:1 to receive ChAdOx1 nCoV-19 at a standard dose, measured using spectrophotometry, or meningococcal group A, C, W, and Y conjugate vaccine (MenACWY) as control. An open-label non-randomised subgroup of ten participants were given two doses of ChAdOx1 nCoV-19 28 days apart. This study was originally planned as a single-dose study and 88 participants in the phase 1 part of the study remain recipients of a single dose
• COVID-19
• Vaccination, Clinical trials
• https://clinica…how/NCT04324606